Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. noratest

NORATEST SIGNED

NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NORATEST project word cloud

Explore the words cloud of the NORATEST project. It provides you a very rough idea of what is the project "NORATEST" about.

prototype    earn    privacy    detecting    direct    first    diagnosis    combined    accumulate    invasive    online    anticipating    ad    computer    2016    profit    cagr    solution    company    medical    innovative    molecular    disease    detect    sales    people    signatures    80m    model    efficiency    biomarkers    duplicating    fast    2026    market    roi    lack    coupled    affordable    32m    2030    total    diseases    ddiagnosis    countries    54m    alzohis    worldwide    accounting    trl6    motivated    charging    care    detectable    detection    algorithm    gt    smart    improvements    producing    pay    hire    efficient    speed    diagnostic    ones    adaptable    leaders    healthy    health    diagnoses    issue    accurate    neurodegenerative    blood    employees    2024    suffering    global    projected    5m    12    tests    2    discriminate    almost    worth    data    scalable    markets    patients    platform    2050    usa    revenue    analytics    alzheimer    advantages    competitive    business    noratest    annual    shows    17    5    reference    360k    stages    dementia    combination   

Project "NORATEST" data sheet

The following table provides information about the project.

Coordinator		 ALZOHIS 

Organization address
address: RUE DU FAUBOURG POISSONNIERE 28
city: PARIS
postcode: 91400
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALZOHIS FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to develop NORATEST, a very unique and innovative e-Health platform producing significant improvements, in terms of speed efficiency, in the detection of neurodegenerative diseases. By means of a novel combination of biomarkers “signatures” detectable in the blood with a state-of-the-art computer algorithm NORATEST can discriminate patients suffering AD from those healthy ones, as well as detecting other neurodegenerative diseases. Our prototype, currently at TRL6, is the first reliable non-invasive molecular diagnostic method able to detect the disease in the very early stages, offering several competitive and innovative advantages such as: Cost-effective novel technology, fast, accurate, early ddiagnosis, data privacy coupled to smart analytics, user-friendly and highly scalable and adaptable platform. Our business model is a pay-per-use combined model of charging per analysis and direct online sales. The global AD market shows great opportunities for us since it was worth €2.5 B in 2016 and is set to reach €12.6 B by 2026 (CAGR of 17.5%). Worldwide we expect a market growth in both established and in developing countries, anticipating >5M annual AD's diagnoses in the two main markets leaders based in Europe (2.5-3.5M diagnoses/year) and USA (1.5-2.5M diagnoses/year) by 2024. Our company goal is to become the reference for AD's diagnosis in Europe. We estimated that in 5 years (end of Phase 2 project), we will accumulate 360K diagnosis tests sales (revenue €54M) accounting for ~2% of the EU and USA market. We expect to hire 40 new technical and sales employees and earn ~€32M profit, with a ROI of 6.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORATEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORATEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More